Biovaxys Technol Stock Price, News & Analysis

BioVaxys Technology Corp. announced a partnership with Millipore-Sigma to produce GLP-grade BVX-1021, a vaccine aimed at the SARS1 coronavirus. This vaccine is part of ongoing research with The Ohio State University, focusing on a broad pan-sarbecovirus vaccine. The study assesses the vaccine's ability to produce virus-neutralizing antibodies against SARS-CoV-2 and related viruses. Notably, BVX-1021 is designed as a booster for individuals already vaccinated or recovered from Covid-19, with potential significant market implications as it targets a wide audience.

BioVaxys Technology Corp. announced that its haptenized SARS-CoV-2 vaccine, BVX-0320, shows no binding to the ACE2 receptor, potentially reducing cardiac risks linked to mRNA vaccines. The study indicates that BVX-0320 may prevent myocarditis while stimulating robust antibody and T cell responses. This development is part of ongoing collaborations, including a partnership with The Ohio State University. The company is advancing its vaccine and plans clinical trials in Europe.

BioVaxys Technology Corp. announced a non-brokered private placement of up to 6,666,667 units at $0.15 per unit, aiming to raise approximately $1,000,000. Each unit includes one common share and one warrant, exercisable at $0.30 for 36 months. The proceeds will be used for working capital, subject to Canadian Securities Exchange approval. BioVaxys is focused on developing vaccines and diagnostics, including a SARS-CoV-2 vaccine and an ovarian cancer vaccine, backed by several patents. The placement closing is anticipated to occur within a week.

BioVaxys Technology Corp announces presentation by Co-Founder and Chief Medical Officer David Berd at the World Vaccine & Immunotherapy Congress in San Diego from November 30-December 2, 2021. Dr. Berd will discuss the potential of haptenized autologous tumor cell vaccines for cancer treatment and the advancement of haptenized viral antigens against SARS-CoV-2 and other viruses. The presentation is scheduled for December 1, 2021 at 17:10 PST. BioVaxys is advancing its platform for viral and oncology vaccines, including a SARS-CoV-2 vaccine aimed at clinical trials.

BioVaxys Technology Corp. (OTCQB: BVAXF) announced positive results from its in vivo study demonstrating the safety and tolerability of CoviDTH, a diagnostic tool for T-cell response to SARS-CoV-2. Conducted with Inotiv, the study showed no adverse effects at doses significantly higher than human levels, except for mild localized redness. The FDA indicated that animal toxicity studies were not required, allowing BioVaxys to move forward with a combined Phase I/II clinical development program. CoviDTH is noted as a cost-effective, point-of-care diagnostic tool validated by recent clinical studies.

BioVaxys Technology Corp. (OTCQB: BVAXF) announced a presentation of preclinical data for its SARS-CoV-2 vaccine candidate, BVX-0320, at the ISIRV-WHO Virtual Congress on October 19-21, 2021. The poster, authored by Chief Medical Officer David Berd, showcases significant antibody and T cell responses in a murine model. The company is advancing its haptenized viral protein technology and preparing for a clinical trial of its cancer vaccine. BioVaxys emphasizes that it does not claim ability to treat SARS-CoV-2 at this time.

BioVaxys Technology Corp. has initiated an in vivo animal toxicology study of its diagnostic tool, CoviDTH, in conjunction with an upcoming IND submission. The study, carried out by Inotiv, Inc., will assess the safety and toxicity of the SARS-CoV-2 s-protein used in CoviDTH. Although the FDA indicated that animal toxicity studies were not required, BioVaxys believes this data could be useful. CoviDTH is designed to evaluate T-cell immune responses in vaccinated or exposed individuals, reinforcing its potential as a low-cost, point-of-care diagnostic.

BioVaxys Technology Corp. announced the engagement of 6 Degrees, a communications firm, to enhance its strategic communications, public and media relations, and social media efforts. The President & COO, Kenneth Kovan, stated that this decision aligns with BioVaxys's growth and aims to increase public awareness. BioVaxys is focused on developing vaccines and diagnostics for viral and oncology applications, including a SARS-CoV-2 vaccine and cancer therapies. The company holds two US patents related to its cancer vaccine and has pending applications for its COVID-19 vaccine technologies.

BioVaxys Technology Corp. announced on September 20, 2021, that it has engaged 6 Degrees, a life sciences communications firm, to enhance its strategic communications and public relations efforts. The partnership aims to improve BioVaxys's visibility as the company advances its oncology and viral vaccine platforms, including a SARS-CoV-2 vaccine and a cell vaccine for ovarian cancer. BioVaxys holds two U.S. patents related to its cancer vaccine and is pursuing additional patents for its COVID-19 technologies.